Guizhou Yibai Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ya Qi Dou

Algemeen directeur

CN¥2.3m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	13.6yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	13.8yrs

Recente managementupdates

Recent updates

CEO

Ya Qi Dou (40 yo)

13.6yrs

Tenure

CN¥2,266,500

Compensatie

Ms. Ya Qi Dou has been a General Manager of Guizhou Yibai Pharmaceutical Co Ltd. since May 14, 2021 and was its Deputy General Manager since April 25, 2011 until May 14, 2021 and has been its Vice Chairman...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ya Qi Dou	GM & Vice Chairman	16.5yrs	CN¥2.27m	0.033% CN¥ 1.0m
Zhiwei Wang	Executive Deputy GM & Director	13.8yrs	CN¥2.27m	0.23% CN¥ 6.9m
Qiling Dou	Chairwoman	29.4yrs	CN¥2.48m	23.57% CN¥ 708.4m
Tao Jiang	Chairman of the Supervisory Board	3.5yrs	geen gegevens	0.0019% CN¥ 57.4k
Jian Pu	Supervisor	3.5yrs	geen gegevens	0.00018% CN¥ 5.4k

13.8yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600594 zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.8 jaar).

Guizhou Yibai Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Guizhou Yibai Pharmaceutical Co., Ltd., Annual General Meeting, May 10, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.053 profit in 3Q 2023)

Guizhou Yibai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: CN¥0.048 loss per share (vs CN¥0.11 profit in 2Q 2023)

Guizhou Yibai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.086 loss per share (vs CN¥0.056 profit in 1Q 2023)

Guizhou Yibai Pharmaceutical Co., Ltd., Annual General Meeting, May 10, 2024

Guizhou Yibai Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024

Guizhou Yibai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE:600594) announces an Equity Buyback for CNY 40 million worth of its shares.

Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE:600594) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.087 in 3Q 2022)

Guizhou Yibai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.096 in 2Q 2022)

Guizhou Yibai Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: EPS: CN¥0.056 (vs CN¥0.064 in 1Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.16 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.096 (vs CN¥0.13 in 2Q 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Now 20% undervalued after recent price drop

Now 22% undervalued

Now 24% undervalued

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.088 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.077 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.076 in 1Q 2020)

New 90-day low: CN¥4.82

New 90-day low: CN¥5.02

New 90-day low: CN¥5.41

New 90-day low: CN¥5.81

New 90-day low: CN¥5.99

New 90-day high - CN¥7.88

Guizhou Yibai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 30, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd